In a Sept. 23 note to investors, Merrill Lynch analyst David W. Munno, who covers antibiotic maker Cubist , a Vicuron competitor, wrote that he suspected Pfizer had received an approvable letter.
In a Sept. 23 note to investors, Merrill Lynch analyst David W. Munno, who covers antibiotic maker Cubist (nasdaq: CBST - news - people ), a Vicuron competitor, wrote that he suspected Pfizer had received an approvable letter.